StockData
Moderna, Inc. logo

Moderna, Inc.

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)

Close on Nov 2, 2026Market cap $88.16BP/E –Yield –

Moderna Recognized from beginning deferred revenue by Year

Recognized from beginning deferred revenue — Collaborations (legacy) ($M) ($M)

Moderna Recognized from beginning deferred revenue: $12M in FY2024, down 61.3% from a year earlier. No newer figure appears in the documents we track.

Latest, FY2024
12
Period ended Dec 31, 2024
Change on a year earlier
-61.3%
31 in FY2023
History
5 years
Since FY2020
Sources
5
Documents cited below

Where the FY2024 figure comes from

Source: Form 10-K (filed 2025-02-21) ↗

Reported in Form 10-Q / 10-K Contract Liabilities.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedRecognized from beginning deferred revenue — Collaborations (legacy) ($M) ($M)Year on yearSource
FY2024Dec 31, 202412-61.3%Form 10-K (filed 2025-02-21) ↗
FY2023Dec 31, 202331+93.8%Form 10-K (filed 2024-02-23) ↗
FY2022Dec 31, 202216-40.7%Form 10-K (filed 2023-02-24) ↗
FY2021Dec 31, 202127-77.9%Form 10-K (filed 2022-02-25) ↗
FY2020Dec 31, 2020122–Form 10-K (filed 2021-02-26) ↗

Cite this data

StockData. (2026). Moderna Recognized from beginning deferred revenue ($M), annual FY2020–FY2024 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/def-rev-rec-collab-leg

See every metric in the Moderna KPI table. Data updated Nov 3, 2026.